Company intelligence / Profile preview

Georgetown Translational Pharmaceuticals

Ownership: Private
Development stage: Phase 2

Overview

GTP developed late-stage and close-to-market improved treatments for central nervous system diseases. Its lead programs included Pain Brake for neuropathic pain (NDA submission planned within ~18 months as of mid-2017), GTP-004 for myasthenia gravis with reduced GI side effects compared to standard therapy, and GTP-011 for motion sickness in elderly patients. The company was acquired by Oxis International in mid-late 2017; its assets became part of GT Biopharma’s broader pipeline that also includes oncology immunotherapies.[1][3][6]

Therapeutic areas: Neurology
Modalities: Small moleculesRepurposed drugsCombination therapy
Industry: Biotech

Drug pipeline

1 asset

GTB-004

Phase 2

Indications: Myasthenia gravis

Partnerships

Oxis International Inc./GT Biopharma Inc.

Beyond the preview

Go deeper on Georgetown Translational Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Georgetown Translational Pharmaceuticals.

Explore the full profile